Business Context and Reporting Period
Company: Albemarle Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1996
Business Overview: Following the March 1, 1996, sale of its alpha olefins, poly alpha olefins, and synthetic alcohol businesses ("Olefins Business") to Amoco Chemical Company, Albemarle is now focused on bromine chemicals, specialty chemicals, and detergents and surfactants.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 1996 | Six Months Ended June 30, 1995 |
|---|---|---|
| Net Sales | $466,210 | $632,962 |
| Gross Profit | $130,884 | $132,125 |
| Gross Margin | 28.1% | 20.9% |
| Operating Profit | $53,823 | $53,121 |
| Net Income | $130,259 | $27,074 |
| Earnings Per Share (Diluted) | $2.10 | $0.41 |
| Cash and Cash Equivalents (End of Period) | $44,292 | $33,732 |
| Long-Term Debt (Total) | $13,423 | $217,112 |
| Operating Cash Flow | ($4,532) | $56,465 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 26% year-over-year, primarily due to the exclusion of the Olefins Business (sold March 1996) and the electronic materials business (sold July 1995). On a comparable basis excluding sold businesses, sales increased 3%.
- Profitability Surge: Net income increased 381% to $130.3 million. This is driven almost entirely by a one-time gain on sale of business of $158.2 million ($94.4 million after tax) from the Olefins divestiture.
- Margin Expansion: Gross profit margin improved to 28.1% from 20.9% due to the removal of lower-margin Olefins operations and foreign exchange gains.
- Debt Reduction: Long-term debt plummeted from $217.1 million to $13.4 million as proceeds from the Olefins sale were used to repay borrowings.
- Share Repurchases: The company utilized sale proceeds to repurchase approximately 9.79 million shares of common stock for $219.4 million via a tender offer and open market purchases.
Guidance, Outlook, and Risks
- Outlook: Management is "cautiously optimistic" regarding bromine chemicals, though European economic sluggishness remains a concern. Specialty chemicals results are expected to improve as high costs associated with naproxen sample production have concluded. Far East sales are currently limited by high inventories but are expected to improve later in the year.
- Cost Management: The company continues to focus on cost reductions following the Olefins sale.
- Capital Expenditures: Expected to be below 1995 levels, financed primarily by operating cash flow.
- Legal Proceedings:
- EPA Settlement: Reached a settlement in principle for a penalty under $100,000 plus a supplemental environmental project (~$150,000).
- OSHA Citation: Received a proposed penalty of $119,000 regarding a fire at the Pasadena, Texas polysilicon plant (operated under contract for MEMC). The company intends to contest this vigorously.
- Environmental Risks: Subject to federal and state Superfund laws; currently in compliance with environmental regulations.
Investor Verification Checklist
- One-Time Gain Impact: Verify the sustainability of earnings by excluding the $158.2 million gain on the Olefins sale; pro forma net income for the six months was $34.9 million.
- Working Capital Usage: Note that operating cash flow was negative ($4.5 million) primarily due to a $37.2 million income tax payment on the sale gain and a $31.8 million increase in working capital.
- Debt Structure: Confirm the drastic reduction in leverage (debt-to-capitalization approx. 2.5%) and the absence of significant long-term debt obligations.
- Share Count: Verify the impact of the 9.79 million share repurchase on future earnings per share calculations.
- Product Mix Shift: Assess the performance of the remaining core businesses (bromine, specialty chemicals) independent of the sold Olefins and electronic materials segments.